Second-Line Treatment Options for Patients with Recurrent Cervical Cancer. Review of Current Treatment and Future Directions - Webinar-Recording - Second-Line Treatment Options for Patients with Recurrent Cervical Cancer. Review of Current Treatment and Future Directions

Recording - Second-Line Treatment Options for Patients with Recurrent Cervical Cancer. Review of Current Treatment and Future Directions

Back to course

Video Transcription

Video Summary

The video discusses recent developments in the field of cervical cancer science. The speaker highlights the role of the International Gynecologic Cancer Society (IGCS) in providing educational programs to inform gynecologic oncology professionals about current and future treatment options for cervical cancer. The speaker mentions the IGCS Education 360 Learning Portal as a valuable resource for accessing educational content in a user-friendly format. The speaker also emphasizes the importance of receiving feedback from professionals to improve the educational offerings. <br /><br />The video then delves into the advancements in cervical cancer treatment, specifically in the areas of immunotherapy, targeted therapy, and antibody drug conjugates (ADCs). The speaker discusses the use of immune checkpoint inhibitors, such as pembrolizumab, and their efficacy in improving overall survival and progression-free survival in patients with recurrent or metastatic cervical cancer. The use of targeted therapy, such as the antibody drug conjugate sodomab vedoten, is also highlighted for its positive response rates and duration of response in patients with advanced cervical cancer.<br /><br />The speaker concludes by acknowledging the progress made in extending the life expectancy of patients with advanced cervical cancer, but also recognizes the challenges of access, cost, and prevention. Ongoing trials are mentioned to further explore the use of immunotherapy in combination with radiation or chemotherapy, as well as the potential for adjuvant therapy. The speaker emphasizes the need for further research and development to continue advancing the treatment options for cervical cancer.

Keywords

cervical cancer science

IGCS Education 360 Learning Portal

immunotherapy

targeted therapy

antibody drug conjugates

advanced cervical cancer

ongoing trials

research and development